Target Price | $157.63 |
Price | $106.59 |
Potential |
47.88%
register free of charge
|
Number of Estimates | 24 |
24 Analysts have issued a price target Neurocrine Biosciences, Inc. 2026 .
The average Neurocrine Biosciences, Inc. target price is $157.63.
This is
47.88%
register free of charge
$192.00
80.13%
register free of charge
$96.00
9.94%
register free of charge
|
|
A rating was issued by 27 analysts: 23 Analysts recommend Neurocrine Biosciences, Inc. to buy, 4 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Neurocrine Biosciences, Inc. stock has an average upside potential 2026 of
47.88%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion $ | 2.36 | 2.65 |
24.81% | 12.62% | |
EBITDA Margin | 26.50% | 22.33% |
20.17% | 15.73% | |
Net Margin | 13.88% | 15.03% |
6.72% | 8.25% |
23 Analysts have issued a sales forecast Neurocrine Biosciences, Inc. 2025 . The average Neurocrine Biosciences, Inc. sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Neurocrine Biosciences, Inc. EBITDA forecast 2025. The average Neurocrine Biosciences, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
19 Neurocrine Biosciences, Inc. Analysts have issued a net profit forecast 2025. The average Neurocrine Biosciences, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | 3.29 | 4.01 |
33.20% | 21.88% | |
P/E | 26.57 | |
EV/Sales | 3.76 |
19 Analysts have issued a Neurocrine Biosciences, Inc. forecast for earnings per share. The average Neurocrine Biosciences, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Neurocrine Biosciences, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Canaccord Genuity |
Locked
➜
Locked
|
Locked | Apr 28 2025 |
Evercore ISI Group |
Locked
➜
Locked
|
Locked | Apr 24 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 22 2025 |
Needham |
Locked
➜
Locked
|
Locked | Apr 15 2025 |
RBC Capital |
Locked
➜
Locked
|
Locked | Apr 14 2025 |
UBS |
Locked
➜
Locked
|
Locked | Apr 04 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Mar 26 2025 |
Analyst Rating | Date |
---|---|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Apr 28 2025 |
Locked
Evercore ISI Group:
Locked
➜
Locked
|
Apr 24 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 22 2025 |
Locked
Needham:
Locked
➜
Locked
|
Apr 15 2025 |
Locked
RBC Capital:
Locked
➜
Locked
|
Apr 14 2025 |
Locked
UBS:
Locked
➜
Locked
|
Apr 04 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Mar 26 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.